title: Hematology: Azacitidine improves survival in myelodysplastic syndromes.
authors.affiliation: Comprehensive Cancer Center, Veterans Administration Connecticut Healthcare System, CT 06516, USA. michal.rose@va.gov
authors.forename: Michal G
authors.initials: MG
authors.lastname: Rose
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006405:Hematology; D006801:Humans; D015337:Multicenter Studies as Topic; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
references.citation: Lancet Oncol. 2009 Mar;10(3):223-32
references.pmid: 19230772
references.citation: J Clin Oncol. 2002 May 15;20(10):2429-40
references.pmid: 12011120
references.citation: Leuk Lymphoma. 2008 Apr;49(4):690-5
references.pmid: 18398735
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3503-10
references.pmid: 17687155
references.citation: N Engl J Med. 2006 Oct 5;355(14):1456-65
references.pmid: 17021321
references.citation: J Clin Oncol. 2002 May 15;20(10):2441-52
references.pmid: 12011121
references.citation: Blood. 2008 Jan 1;111(1):86-93
references.pmid: 17893227
references.citation: J Clin Oncol. 2011 May 20;29(15):1987-96
references.pmid: 21483003
references.citation: J Clin Oncol. 2009 Apr 10;27(11):1850-6
references.pmid: 19255328
references.citation: Blood. 1997 Mar 15;89(6):2079-88
references.pmid: 9058730